MoonLake Immunotherapeutics (MLTX) fair value analysis
Nasdaq · Updated 2026-10-19
MLTX price how computed
Valuation status
No fair-value estimate yetMLTX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for MLTX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $9.55
- Sector
- Healthcare
- 12-month range
- $9.46–$22.16
- Market cap
- $813M
- From 52-week high
- -56.9%
- Shares outstanding
- 85.1M
- Rank in Healthcare by quality score
- #251 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for the treatment of cancer and other serious diseases. The company is headquartered in the United States and operates as a publicly traded entity on the Nasdaq exchange.
MLTX currently ranks #251 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $813M
- P/E (trailing)
- n/m
- EPS (TTM)
- $-3.84
- Debt / equity
- 0.24
- Shares outstanding
- 85.1M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 25 · oversold
- 50-day average
- $13.57
- 200-day average
- $16.61
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▲ beat (+6.7%)
2026-03 ▼ miss (-6.5%)
2025-12 ▲ beat (+6.0%)
2025-09 ▼ miss (-23.6%)
2025-06 ▼ miss (-14.5%)
2025-03 ▲ beat (+14.3%)
2024-12 ▼ miss (-22.0%)
2024-09 ▼ miss (-24.4%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 11 buy · 2 hold · 2 sell (15 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $28.5
- Target vs last price
- +198.4%
What our data shows for MLTX
- Shares are trading in the lower third of their 12-month price range of $9.46–$22.16.
- The 14-day relative strength index sits at an oversold 25.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- MLTX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the MLTX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — MLTX's RSI zone shifted from neutral to oversold this week, indicating that the stock's momentum has weakened according to this technical indicator. The stock remains in the Healthcare sector with a valuation verdict currently awaiting full analysis.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for MLTX showed movement this week as the RSI zone transitioned from oversold to neutral territory. The stock remains in the Healthcare sector with a valuation verdict of awaiting full valuation.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is MLTX stock undervalued?
TickrTrends has no fair-value estimate for MLTX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is MLTX's TickrTrends verdict?
MLTX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does MLTX compare to other Healthcare stocks?
MLTX ranks #251 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is MLTX overbought or oversold?
MLTX's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does MLTX report earnings next?
MLTX's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does MLTX usually beat earnings estimates?
Over its last 8 reported quarters MLTX beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MLTX?
Of 15 analysts covering MLTX, 11 rate it a buy, 2 a hold and 2 a sell - buy-leaning, with a consensus price target of $28.5 (+198.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.